ASCO 2025 | Clonal hematopoiesis monitoring as a future biomarker in mCRPC

Aslı Doğa Munzur • 31 May 2025

ASCO 2025

Aslı Doğa Munzur, BSc, Vancouver Prostate Centre, Vancouver, Canada, speaks on the potential of clonal hematopoiesis (CH) as a biomarker to predict future risk of blood disorders or secondary malignancies in metastatic castration-resistant prostate cancer (mCRPC). Although it is currently unknown what triggers CH to undergo malignant transformation, more data from the ongoing Phase II trial (NCT03392428) will shed further light on what CH means in terms of patient selection and risk stratification before therapy. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.